{"id":68073,"date":"2026-06-12T15:08:26","date_gmt":"2026-06-12T07:08:26","guid":{"rendered":"https:\/\/flcube.com\/?p=68073"},"modified":"2026-06-12T15:08:27","modified_gmt":"2026-06-12T07:08:27","slug":"takedas-zasocitinib-demonstrates-superior-efficacy-over-deucravacitinib-in-phase-iii-psoriasis-trial-with-35-pasi-100-response-rate","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=68073","title":{"rendered":"Takeda&#8217;s Zasocitinib Demonstrates Superior Efficacy Over Deucravacitinib in Phase III Psoriasis Trial with 35% PASI 100 Response Rate"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Takeda Pharmaceutical Company Limited<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/4502:TYO\">TYO: 4502<\/a>; <a href=\"https:\/\/www.google.com\/finance\/quote\/TAK:NYSE\">NYSE: TAK<\/a>) announced <strong>positive topline results<\/strong> from a <strong>Phase III, randomized, multicenter, double-blind study<\/strong> comparing <strong>zasocitinib (TAK-279)<\/strong> with <strong>deucravacitinib<\/strong> in adults with <strong>moderate-to-severe plaque psoriasis (PsO)<\/strong>. At <strong>week 16<\/strong>, more than <strong>35% of patients treated with zasocitinib achieved complete skin clearance (PASI 100)<\/strong>, representing a response rate <strong>more than 2.5 times higher<\/strong> than that of deucravacitinib.<\/p>\n\n\n\n<h2 id=\"h-clinical-trial-results\" class=\"wp-block-heading\">Clinical Trial Results<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Zasocitinib<\/th><th>Deucravacitinib<\/th><th>Relative Benefit<\/th><\/tr><\/thead><tbody><tr><td><strong>PASI 100 at Week 16<\/strong><\/td><td>&gt;35%<\/td><td>~14%<\/td><td><strong>&gt;2.5x higher<\/strong><\/td><\/tr><tr><td><strong>Efficacy Separation<\/strong><\/td><td>Emerged by Week 8<\/td><td>Baseline comparator<\/td><td>Early differentiation<\/td><\/tr><tr><td><strong>Study Design<\/strong><\/td><td>Phase III, randomized, multicenter, double-blind<\/td><td>Same trial<\/td><td>Head-to-head comparison<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Adults with moderate-to-severe plaque psoriasis<\/td><td>Same population<\/td><td>Homogeneous cohort<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Zasocitinib (TAK-279) \u2013 <strong>investigational, next-generation oral TYK2 inhibitor<\/strong><\/li>\n\n\n\n<li><strong>Selectivity:<\/strong> <strong>Highly selective and potent<\/strong> tyrosine kinase 2 (TYK2) inhibition<\/li>\n\n\n\n<li><strong>Duration:<\/strong> Maintains <strong>24-hour inhibition<\/strong> of IL-23 and other core disease-driving immune pathways<\/li>\n\n\n\n<li><strong>Dosing:<\/strong> <strong>Once-daily oral pill<\/strong> for convenient administration<\/li>\n\n\n\n<li><strong>Development Status:<\/strong> <strong>Investigational compound<\/strong> \u2013 not yet approved by any regulatory authority<\/li>\n\n\n\n<li><strong>Therapeutic Potential:<\/strong> Could become a <strong>leading oral treatment option<\/strong> for psoriasis patients<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-expanded-development-program\" class=\"wp-block-heading\">Expanded Development Program<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Indication<\/th><th>Development Stage<\/th><th>Status<\/th><\/tr><\/thead><tbody><tr><td><strong>Plaque Psoriasis (PsO)<\/strong><\/td><td>Phase III<\/td><td>Positive topline results<\/td><\/tr><tr><td><strong>Psoriatic Arthritis<\/strong><\/td><td>Phase III<\/td><td>Currently evaluating<\/td><\/tr><tr><td><strong>Crohn&#8217;s Disease<\/strong><\/td><td>Phase II<\/td><td>Active studies<\/td><\/tr><tr><td><strong>Ulcerative Colitis<\/strong><\/td><td>Phase II<\/td><td>Active studies<\/td><\/tr><tr><td><strong>Vitiligo<\/strong><\/td><td>Phase II<\/td><td>Active studies<\/td><\/tr><tr><td><strong>Hidradenitis Suppurativa (HS)<\/strong><\/td><td>Phase II<\/td><td>Active studies<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The broad development program demonstrates Takeda&#8217;s confidence in zasocitinib&#8217;s potential across multiple immune-mediated inflammatory diseases.<\/p>\n\n\n\n<h2 id=\"h-market-context-amp-competitive-landscape\" class=\"wp-block-heading\">Market Context &amp; Competitive Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Current TYK2 Leader:<\/strong> <strong>Deucravacitinib<\/strong> (Sotyktu, Bristol Myers Squibb) is the first approved TYK2 inhibitor for psoriasis, with PASI 100 rates of approximately 14-21% at 16 weeks in clinical trials<\/li>\n\n\n\n<li><strong>Market Opportunity:<\/strong> Global psoriasis therapeutics market projected to exceed <strong>USD 25 billion by 2030<\/strong><\/li>\n\n\n\n<li><strong>Competitive Advantage:<\/strong> Zasocitinib&#8217;s <strong>>35% PASI 100 rate<\/strong> represents a potentially significant efficacy improvement over current standard-of-care oral therapies<\/li>\n\n\n\n<li><strong>Oral vs. Biologic:<\/strong> Oral TYK2 inhibitors compete with injectable biologics (TNF, IL-17, IL-23 inhibitors) that typically achieve PASI 100 rates of 30-50% but require injections or infusions<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-implications\" class=\"wp-block-heading\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First-Mover vs. Best-in-Class:<\/strong> While BMS has first-mover advantage with deucravacitinib, Takeda&#8217;s superior efficacy data positions zasocitinib as a potential best-in-class TYK2 inhibitor<\/li>\n\n\n\n<li><strong>Pipeline Diversification:<\/strong> Success in psoriasis could accelerate development timelines for other indications in the robust Phase II\/III program<\/li>\n\n\n\n<li><strong>Commercial Potential:<\/strong> High PASI 100 rates combined with oral dosing could capture significant market share from both conventional oral therapies and biologics<\/li>\n\n\n\n<li><strong>Regulatory Pathway:<\/strong> Positive Phase III data supports upcoming regulatory submissions in major markets including U.S., EU, and Japan<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical trial results, regulatory pathways, and commercial potential for zasocitinib. Actual results may differ due to risks including final data analysis, regulatory decisions, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) announced positive topline results from a Phase&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[874,345,1141],"class_list":["post-68073","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-nyse-tak","tag-takeda","tag-tyo-4502"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Takeda&#039;s Zasocitinib Demonstrates Superior Efficacy Over Deucravacitinib in Phase III Psoriasis Trial with 35% PASI 100 Response Rate - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) announced positive topline results from a Phase III, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279) with deucravacitinib in adults with moderate-to-severe plaque psoriasis (PsO). At week 16, more than 35% of patients treated with zasocitinib achieved complete skin clearance (PASI 100), representing a response rate more than 2.5 times higher than that of deucravacitinib.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=68073\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Takeda&#039;s Zasocitinib Demonstrates Superior Efficacy Over Deucravacitinib in Phase III Psoriasis Trial with 35% PASI 100 Response Rate\" \/>\n<meta property=\"og:description\" content=\"Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) announced positive topline results from a Phase III, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279) with deucravacitinib in adults with moderate-to-severe plaque psoriasis (PsO). At week 16, more than 35% of patients treated with zasocitinib achieved complete skin clearance (PASI 100), representing a response rate more than 2.5 times higher than that of deucravacitinib.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=68073\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-12T07:08:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-12T07:08:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68073#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68073\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Takeda&#8217;s Zasocitinib Demonstrates Superior Efficacy Over Deucravacitinib in Phase III Psoriasis Trial with 35% PASI 100 Response Rate\",\"datePublished\":\"2026-06-12T07:08:26+00:00\",\"dateModified\":\"2026-06-12T07:08:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68073\"},\"wordCount\":457,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"NYSE: TAK\",\"Takeda\",\"TYO: 4502\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68073#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68073\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=68073\",\"name\":\"Takeda's Zasocitinib Demonstrates Superior Efficacy Over Deucravacitinib in Phase III Psoriasis Trial with 35% PASI 100 Response Rate - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-12T07:08:26+00:00\",\"dateModified\":\"2026-06-12T07:08:27+00:00\",\"description\":\"Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) announced positive topline results from a Phase III, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279) with deucravacitinib in adults with moderate-to-severe plaque psoriasis (PsO). At week 16, more than 35% of patients treated with zasocitinib achieved complete skin clearance (PASI 100), representing a response rate more than 2.5 times higher than that of deucravacitinib.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68073#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68073\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68073#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Takeda&#8217;s Zasocitinib Demonstrates Superior Efficacy Over Deucravacitinib in Phase III Psoriasis Trial with 35% PASI 100 Response Rate\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Takeda's Zasocitinib Demonstrates Superior Efficacy Over Deucravacitinib in Phase III Psoriasis Trial with 35% PASI 100 Response Rate - Insight, China&#039;s Pharmaceutical Industry","description":"Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) announced positive topline results from a Phase III, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279) with deucravacitinib in adults with moderate-to-severe plaque psoriasis (PsO). At week 16, more than 35% of patients treated with zasocitinib achieved complete skin clearance (PASI 100), representing a response rate more than 2.5 times higher than that of deucravacitinib.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=68073","og_locale":"en_US","og_type":"article","og_title":"Takeda's Zasocitinib Demonstrates Superior Efficacy Over Deucravacitinib in Phase III Psoriasis Trial with 35% PASI 100 Response Rate","og_description":"Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) announced positive topline results from a Phase III, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279) with deucravacitinib in adults with moderate-to-severe plaque psoriasis (PsO). At week 16, more than 35% of patients treated with zasocitinib achieved complete skin clearance (PASI 100), representing a response rate more than 2.5 times higher than that of deucravacitinib.","og_url":"https:\/\/flcube.com\/?p=68073","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-12T07:08:26+00:00","article_modified_time":"2026-06-12T07:08:27+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=68073#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=68073"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Takeda&#8217;s Zasocitinib Demonstrates Superior Efficacy Over Deucravacitinib in Phase III Psoriasis Trial with 35% PASI 100 Response Rate","datePublished":"2026-06-12T07:08:26+00:00","dateModified":"2026-06-12T07:08:27+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=68073"},"wordCount":457,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["NYSE: TAK","Takeda","TYO: 4502"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=68073#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=68073","url":"https:\/\/flcube.com\/?p=68073","name":"Takeda's Zasocitinib Demonstrates Superior Efficacy Over Deucravacitinib in Phase III Psoriasis Trial with 35% PASI 100 Response Rate - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-12T07:08:26+00:00","dateModified":"2026-06-12T07:08:27+00:00","description":"Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) announced positive topline results from a Phase III, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279) with deucravacitinib in adults with moderate-to-severe plaque psoriasis (PsO). At week 16, more than 35% of patients treated with zasocitinib achieved complete skin clearance (PASI 100), representing a response rate more than 2.5 times higher than that of deucravacitinib.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=68073#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=68073"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=68073#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Takeda&#8217;s Zasocitinib Demonstrates Superior Efficacy Over Deucravacitinib in Phase III Psoriasis Trial with 35% PASI 100 Response Rate"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68073","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=68073"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68073\/revisions"}],"predecessor-version":[{"id":68074,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68073\/revisions\/68074"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=68073"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=68073"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=68073"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}